WebKiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong … Web23 uur geleden · Price To Cash Flow is a widely used stock evaluation measure. ... Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates 02/28/23 …
Kiniksa Pharmaceuticals (KNSA) stock Forecast for 2024 – 2026
WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price … Web23 uur geleden · Price To Cash Flow is a widely used stock evaluation measure. ... Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates 02/28/23-10:25AM EST Zacks. david culbertson rome ny
Kiniksa Pharmaceuticals (KNSA) Stock Price & Analysis
Web6 jan. 2024 · In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $11.10. According to TipRanks.com, Bayko is a 4-star analyst with an average return of 9.1% and a 45.4% success rate. WebKiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Zacks. WebKiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2024 and full-year 2024 … gas mach number calculator